Mina Sooch withdraws her slate of nominees at Opus Genetics, Inc (IRD)

Market Cap: $42 million | Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. 

On February 7, 2025, Mina Sooch, founder of Opus Genetics, has nominated a seven-member "Restore Value Slate" for the Board, citing strategic, management, and capital allocation failures that led to an 80% stock decline over 22 months. The group, holding 4.1% of shares, aims to restore governance, curb unnecessary spending, and refocus on Ryzumvi™, a high-value FDA-approved asset, rather than the capital-intensive gene therapy pivot executed without shareholder approval. Source

On March 21, 2025, Mina Sooch filed proxy materials seeking support for her nominees

On April 1, 2025, the Restore Value Slate launched a website to communicate with the Company’s stockholders. The website address is https://restorevalueslate.com/.

On April 9, 2025, Ms. Sooch determined to withdraw her slate of nominees for election to the Board at the Annual Meeting. Source